One explanation lies on the correlation with IDH mutation status, especially in neural subtypes and low-grade gliomas, which determines hypermethylation of genome regions, including those involved in the transcription immune-response factors, such as human leukocyte antigen, decreasing MHC-I-mediated antigen presentation [121]. This evidence concerns the gene IDH2 and central nervous system cancer.